Recombinant kinase inhibition by reversine
Biochemical assay · Recombinant human full-length MPS1, MPS1 kinase domain and AURORA B–INCENP; comparison panel of mitotic kinases [1]
Reversine inhibited MPS1 more potently than AURORA B in the reported enzyme assays. The broader panel provides a bounded selectivity control, not evidence of universal target specificity.
| Endpoint | Reported result | Reference |
|---|---|---|
| Full-length human MPS1 activity toward MAD1–MAD2 | IC50 2.8 nM | [1] |
| MPS1 kinase-domain activity toward MAD1–MAD2 | IC50 6 nM | [1] |
| Human AURORA B(1–344)–INCENP(835–903) activity toward histone H3 | IC50 98.5 nM | [1] |
| Activity of BUB1, NEK2A, TAO1, PLK1, CDK1–CYCLIN B, HASPIN and PRP4 | Qualitative control result No significant inhibition reported at 1 µM reversine | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Reversine titrations for IC50 determination; 1 µM for the comparison panel
- Exposure duration
- 1 h
- Method
- In-vitro phosphorylation at 30°C with 50 µM ATP; radiolabeled phosphate incorporation, SDS-PAGE and autoradiography
- Vehicle
- DMSO; methods specify DMSO or DMSO-dissolved drug in reaction mixtures
- Reported limits
- Exact replicate n is not stated in Figure 1 caption. Compound supplier/lot and salt specification were not established from the selected original material.
Methods and source locations
Compound reported in the paper: Reversine
Evidence concerns reported reversine material; no salt conversion, current A13250 lot equivalence, clinical efficacy or dosing recommendation is established.
Results: Reversine is a potent MPS1 inhibitor; Figure 1A–D and caption; Materials and methods: In vitro kinase assays and Purification of mitotic kinases
Full-length human MPS1 activity toward MAD1–MAD2: Radiometric kinase assay; 50 µM ATP; 1 h at 30°C; densitometry and fitted log-dose response; graph error bars mean ± SEM. Replicate n not stated in the Figure 1 caption. — Results: Reversine is a potent MPS1 inhibitor; Figure 1A–D and caption; Materials and methods: In vitro kinase assays and Purification of mitotic kinases
MPS1 kinase-domain activity toward MAD1–MAD2: Same Figure 1 radiometric assay framework; endpoint is enzyme inhibition, not a cell treatment dose. — Results: Reversine is a potent MPS1 inhibitor; Figure 1A–D and caption; Materials and methods: In vitro kinase assays and Purification of mitotic kinases
Human AURORA B(1–344)–INCENP(835–903) activity toward histone H3: Radiometric kinase assay at 50 µM ATP; Figure 1A error bars mean ± SEM. — Results: Reversine is a potent MPS1 inhibitor; Figure 1A–D and caption; Materials and methods: In vitro kinase assays and Purification of mitotic kinases
Activity of BUB1, NEK2A, TAO1, PLK1, CDK1–CYCLIN B, HASPIN and PRP4: Figure 1B control lanes versus reversine; BI2536 and roscovitine positive inhibition controls for PLK1 and CDK1. This is not a proteome-wide selectivity test. — Results: Reversine is a potent MPS1 inhibitor; Figure 1A–D and caption; Materials and methods: In vitro kinase assays and Purification of mitotic kinases